Indeed, the SARS-CoV-2 receptor that is the subject of most studies is the angio-tensin-converting enzyme 2 (ACE2), and yet several studies examining the impact of its inhibition showed that the effectiveness of inhibiting ACE2 as a therapeutic option for COVID-19 patients seems questionable [37,38]. This evidence concerns the gene ACE2 and COVID-19.